Edit
Greenbrook TMS NeuroHealth Centers
https://www.greenbrooktms.com/Last activity: 15.08.2024
Active
Greenbrook TMS NeuroHealth Centers is a leading provider of TMS therapy for the treatment of depression. When your current treatment is not enough, Transcranial Magnetic Stimulation Therapy (TMS therapy) is a safe and effective medical treatment for individuals diagnosed with depression that can be used in conjunction with medication or as a stand-alone treatment.
TMS Therapy applies magnetic stimulation to specific areas of the brain involved in mood regulation- areas known to be under active in people suffering with depression. TMS therapy is:
* Non-systemic: nothing enters the bloodstream.
* Non-invasive: nothing is inserted or implanted into the body.
* Non-sedating: patient remains awake and alert during treatment and can resume usual routine, including driving.
* No drug-related side effects.
* FDA-cleared: two out of every three patients have a reduction in depression scores after a four-week treatment period.
* Covered by most insurance plans, with Medicare and Medicaid accepted at various center locations. We assist patients with the reimbursement and financing process.
To learn more about Greenbrook TMS and to find out if TMS therapy is right for you:
*Visit our website: www.greenbrooktms.com
*Take our quiz: www.greenbrooktms.com/quiz
*Schedule your free consultation: www.greenbrooktms.com/free-consultation
*Call us at 855-940-4867
Greenbrook TMS moderates all comments and reserves the right to remove your comment. View our Social Media Policy here: https://www.greenbrooktms.com/privacy
TMS Therapy applies magnetic stimulation to specific areas of the brain involved in mood regulation- areas known to be under active in people suffering with depression. TMS therapy is:
* Non-systemic: nothing enters the bloodstream.
* Non-invasive: nothing is inserted or implanted into the body.
* Non-sedating: patient remains awake and alert during treatment and can resume usual routine, including driving.
* No drug-related side effects.
* FDA-cleared: two out of every three patients have a reduction in depression scores after a four-week treatment period.
* Covered by most insurance plans, with Medicare and Medicaid accepted at various center locations. We assist patients with the reimbursement and financing process.
To learn more about Greenbrook TMS and to find out if TMS therapy is right for you:
*Visit our website: www.greenbrooktms.com
*Take our quiz: www.greenbrooktms.com/quiz
*Schedule your free consultation: www.greenbrooktms.com/free-consultation
*Call us at 855-940-4867
Greenbrook TMS moderates all comments and reserves the right to remove your comment. View our Social Media Policy here: https://www.greenbrooktms.com/privacy
Location: United States, Virginia, McLean
Employees: 201-500
Total raised: $40.89M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | 1315 Capit... | 1315capita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.01.2021 | - | $30M | - |
| 27.05.2020 | - | $10.89M | - |
Mentions in press and media 17
| Date | Title | Description |
| 15.08.2024 | Greenbrook TMS: Navigating Legal Waters and Financial Challenges | Greenbrook TMS Inc. is in the spotlight, facing both legal and financial hurdles. The company recently announced a settlement with Benjamin Klein, a significant player in its operational landscape. This settlement, valued at $800,000, inclu... |
| 13.08.2024 | GREENBROOK TMS REPORTS SECOND QUARTER OPERATIONAL AND FINANCIAL RESULTS | TORONTO, Aug. 13, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTCQB: GBNHF) ("Greenbrook" or the "Company") today announced its second quarter 2024 ("Q2 2024") operational and financial results. All values in this... |
| 09.08.2024 | GREENBROOK ANNOUNCES SETTLEMENT OF LAWSUIT WITH BENJAMIN KLEIN | TORONTO, Aug. 9, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTC: GBNHF) ("Greenbrook" or the "Company") announced it has entered into a settlement agreement and release (the "Settlement Agreement") with Mr. Benja... |
| 14.05.2024 | GREENBROOK TMS REPORTS FIRST QUARTER OPERATIONAL AND FINANCIAL RESULTS | TORONTO, May 14, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTCQB: GBNHF) ("Greenbrook" or the "Company") today announced its first quarter 2024 ("Q1 2024") operational and financial results. All values in this n... |
| 14.07.2022 | Greenbrook TMS Announces Closing of Success TMS Acquisition and US$75 Million Credit Facil... | - |
| 29.10.2021 | Greenbrook TMS Announces Dates for Its Third Quarter 2021 Financial Results - Form 6-K | Greenbrook TMS Announces Dates for Its Third Quarter 2021 Financial Results TORONTO--(BUSINESS WIRE)--October 28, 2021--Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) ("Greenbrook" or the "Company"), will release its thir... |
| 22.09.2021 | GREENBROOK TMS : ANNOUNCES INCREASE TO BOUGHT DEAL FINANCING TO US$11.5 MILLION (Form 6-K) | GREENBROOK TMS ANNOUNCES INCREASE TO BOUGHT DEAL FINANCING TO US$11.5 MILLION September 22, 2021 - Toronto, Canada - Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) ("Greenbrook" or the "Company"), a leading provider of T... |
| 22.09.2021 | Greenbrook TMS : Announces Increase to Bought Deal Financing to US$11.5 Million | Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce that, due to strong demand, the Company has... |
| 21.09.2021 | Greenbrook TMS : to Acquire Achieve TMS East and Central and Announces US$10 Million Bought Deal Public Offering | Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it has entered into a purchase agreement purs... |
| 29.04.2021 | BRAINSWAY LTD. BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers | CRESSKILL, N.J. and JERUSALEM, April 29, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive treatment of brain disorders, today announced the distributio... |
Show more